EPCO-22. LONGITUDINAL MOLECULAR CHARACTERIZATION IDENTIFIES TREATMENT DRIVEN EVOLUTION OF OLIGODENDROGLIOMA
Chowdhury T, Johnson K, Kocakavuk E, Heo C, Ye G, Ghospurkar P, Wade T, Barnholtz-Sloan J, Costello J, Elliott C, French P, Golebiewska A, Hermes B, Hong C, Horbinski C, Khasraw M, LaViolette P, Li K, Lipp E, Lowman A, McCortney K, Moon H, Ng H, Padovan M, Paek S, Vallentgoed W, Vaubel R, Wesseling P, Westcott K, Consortium G, Varn F, Verhaak R. EPCO-22. LONGITUDINAL MOLECULAR CHARACTERIZATION IDENTIFIES TREATMENT DRIVEN EVOLUTION OF OLIGODENDROGLIOMA. Neuro-Oncology 2023, 25: v128-v128. PMCID: PMC10639435, DOI: 10.1093/neuonc/noad179.0485.Peer-Reviewed Original ResearchWhole-exome sequencingPI3K pathwaySingle-nucleus RNA sequencingStem-like cellsPatient mortalityChromosome 4 lossPIK3R1 mutationsTreatment resistanceFUBP1 mutationsAggressive phenotypeMost oligodendrogliomasOligodendroglioma patientsChromosome arms 1pRecurrenceAdministration dateSomatic copy number alterationsCopy number alterationsMutational signature analysisOligodendrogliomasRecurrent samplesTERT promoterExome sequencingK pathwayCommon mutationsMolecular changes